

Recent Results in Cancer Research  
P.M. Schlag · H.-J. Senn *Series Editors*

Andrea Tannapfel  
*Editor*

# Malignant Mesothelioma

Indexed in PubMed/Medline

 Springer

**Managing Editors**

**P.M. Schlag, Berlin    H.-J. Senn, St. Gallen**

**Associate Editors**

**P. Kleihues, Zürich    F. Stiefel, Lausanne  
B. Groner, Frankfurt    A. Wallgren, Göteborg**

**Founding Editor**

**P. Rentchnik, Geneva**



Andrea Tannapfel  
(Editor)

# Malignant Mesothelioma

 Springer

*Editor*

Prof. Andrea Tannapfel  
Institut für Pathologie  
Ruhr-Universität Bochum  
BG Kliniken Bergmannsheil  
Bürke-de-la-Camp Platz 1  
44789 Bochum, Germany  
andrea.tannapfel@ruhr-uni-bochum.de

ISBN 978-3-642-10861-7      e-ISBN 978-3-642-10862-4  
DOI 10.1007/978-3-642-10862-4  
Springer Heidelberg Dordrecht London New York

Library of Congress Control Number: 2011923338

© Springer-Verlag Berlin Heidelberg 2011

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

*Cover design:* estudioCalamar Figueres/Berlin

Printed on acid-free paper

Springer is part of Springer Science + Business Media ([www.springer.com](http://www.springer.com))

# Preface

Malignant mesothelioma is a rare and aggressive tumor arising from the mesothelium. Pleural, peritoneal, and pericardial mesothelioma are possible entities according to the site of origin.

Diffuse malignant mesothelioma is strongly associated with exposure to asbestos and was first referred by Selikoff in 1965 as a “signal tumor” because of its close association with occupational and environmental exposure to asbestos.

There is a clear positive correlation between historical asbestos exposure and deaths caused by mesothelioma. Approximately, 2500 patients in the United States of America and 1000 patients in Germany annually are diagnosed with malignant mesothelioma. The incidence peak of mesothelioma will be reached in the next 10–20 years due to the extended latency period of about 30–40 years or more after exposure.

This issue of “Recent Results in Cancer Research” – Malignant Mesothelioma – is a comprehensive compilation of all topics related to asbestos and mesothelioma, written by well-known experts in their fields.

We intend to provide a broad overview of mineralogy of asbestos, analysis for lung tissue fiber content, and epidemiology of this disease.

The book also refers to all new diagnostic pathways like imaging, pathohistological as well as molecular approaches, genetic and molecular biological characteristics, and potential use of biomarkers for screening of mesothelioma.

Recent developments and novel approaches in surgery, chemotherapy, and radiotherapy of malignant mesothelioma are outlined by experts in this field.

The chapter about mineralogy of asbestos emphasizes the pivotal role of different physicochemical and biological features of chrysotile and amphibole asbestos for understanding the different hazards of exposure.

An outstanding team of international leading experts have contributed to this book. It is addressed to oncologists, radiologists, thoracic surgeons, pathologists, and pulmonologists with the intention to provide a scientific-based up-to-date view on mesothelioma research, diagnosis, and therapy strategies. A comprehensive understanding of all aspects of this disease will be the foundation to perform successful future laboratory research and clinical studies.

Andrea Tannapfel  
Volker Neumann



# Contents

<b>1 Mineralogy of Asbestos</b> . . . . .	1
Thomas A. Sporn	
1.1 Introduction and Historical Background . . . . .	1
1.2 Geologic and Mineralogic Features . . . . .	2
1.3 Distribution and Physicochemical Properties of Chrysotile . . . . .	4
1.4 Distribution and Physicochemical Properties of the Amphibole Species . . . . .	7
1.5 Identification and Characterization of Asbestos . . . . .	9
References . . . . .	10
<b>2 Epidemiology of Mesothelioma and Historical Background</b> . . . . .	13
J.E. Craighead	
References . . . . .	23
<b>3 Imaging of Mesothelioma</b> . . . . .	27
Ritu R. Gill	
3.1 Introduction . . . . .	27
3.2 Patterns of Presentation and Imaging Features . . . . .	28
3.3 Preoperative Evaluation of MPM. . . . .	29
3.4 Postoperative Evaluation . . . . .	36
3.5 Unresectable Disease . . . . .	36
3.6 Future Directions . . . . .	38
3.7 Summary . . . . .	41
References . . . . .	41
<b>4 Biopsy Techniques for the Diagnosis of Mesothelioma</b> . . . . .	45
J. Walters and Nick A. Maskell	
4.1 Introduction . . . . .	45
4.2 Clinical Presentation . . . . .	46

4.3	Investigation of Pleural Effusion . . . . .	46
4.3.1	Cytology . . . . .	46
4.4	Investigation of Pleural Thickening with No Effusion . . . . .	47
4.5	Percutaneous Pleural Biopsy Techniques . . . . .	47
4.5.1	Abrams Needle . . . . .	47
4.5.2	Radiologically Guided Percutaneous Pleural Biopsy . . . . .	48
4.5.3	Positron Emission Tomography (PET) CT . . . . .	49
4.6	Thoracoscopy . . . . .	49
4.6.1	Local Anaesthetic Thoracoscopy . . . . .	50
4.6.2	Video-Assisted Thoracoscopic Surgery . . . . .	51
4.7	Open Biopsy . . . . .	52
4.8	Prophylactic Radiotherapy . . . . .	52
	References . . . . .	53
<b>5</b>	<b>Pathohistological Diagnosis and Differential Diagnosis . . . . .</b>	<b>57</b>
	Iris Tischoff, Matthias Neid, Volker Neumann, and Andrea Tannapfel	
5.1	Introduction . . . . .	58
5.2	Malignant Mesothelioma of the Pleura . . . . .	58
5.2.1	Morphology . . . . .	58
5.3	Differential Diagnosis of Malignant Mesothelioma and Pleural Metastases . . . . .	61
5.3.1	Morphological Differences . . . . .	61
5.3.2	Immunohistochemistry . . . . .	62
5.4	Reactive Versus Neoplastic Mesothelial Proliferation . . . . .	65
5.5	Primary Pleural Tumours Other than Malignant Mesothelioma . . . . .	66
5.5.1	Peritoneal Mesothelioma . . . . .	67
5.5.2	Malignant Mesothelioma of Tunica Vaginalis Testis . . . . .	69
5.5.3	Well-Differentiated Papillary Mesothelioma . . . . .	69
5.5.4	Prognosis and Predictive Factors . . . . .	70
5.5.5	Differential Diagnosis . . . . .	71
5.5.6	Benign Lesions . . . . .	71
5.5.7	Malignant Lesions . . . . .	72
5.5.8	Immunohistochemistry . . . . .	73
5.6	Primary Peritoneal Carcinoma/Metastases of Serous Ovarian Cancer Versus Malignant Peritoneal Mesothelioma . . . . .	74
	References . . . . .	75
<b>6</b>	<b>Mesothelioma and Analysis of Tissue Fiber Content . . . . .</b>	<b>79</b>
	Volker Neumann, Stefan Löseke, and Andrea Tannapfel	
6.1	Introduction . . . . .	80
6.2	Techniques for Analysis of Pulmonary Mineral-Fiber Content . . . . .	82
6.2.1	Lung Tissue Digests . . . . .	82
6.3	Methods for Mineral Fiber Analysis . . . . .	83
6.3.1	Light Microscopy (LM) . . . . .	83

6.3.2	Electron Microscopy . . . . .	83
6.3.3	Comparability of Results Generated by Light or Electron Microscopy . . . . .	84
6.3.4	Reference Population and Background Lung Asbestos Burden . . . . .	84
6.3.5	Asbestos Bodies and Fiber Counting. . . . .	84
6.4	Asbestos Lung Tissue Content in Patients with Mesothelioma. . . . .	85
6.4.1	Light Microscopy. . . . .	85
6.4.2	Electron Microscopy . . . . .	86
6.4.3	Asbestos Content and Fiber Dimensions in Pleural Samples . . . . .	86
6.5	Discussion . . . . .	87
6.5.1	Asbestos Bodies and Fiber Burden of the Lung . . . . .	87
6.5.2	Latency Period and Mean Age at Diagnosis of Mesothelioma . . . . .	88
6.5.3	Clearance and Biopersistence of Asbestos Fibers . . . . .	88
6.5.4	Carcinogenic Potency of Asbestos Fibers . . . . .	89
6.5.5	Peritoneal Mesothelioma . . . . .	89
6.5.6	Asbestos-Associated Mesothelioma and Other Possible Causes of Malignant Mesothelioma . . . . .	89
6.5.7	Threshold or Cut-off Level . . . . .	90
6.6	Conclusion. . . . .	90
	References . . . . .	90
<b>7</b>	<b>Surgical Therapy of Mesothelioma . . . . .</b>	<b>97</b>
	David Rice	
7.1	Introduction . . . . .	97
7.2	Natural History . . . . .	98
7.3	Diagnosis . . . . .	98
7.3.1	Video-Assisted Thoracoscopy . . . . .	98
7.4	Staging . . . . .	100
7.4.1	Laparoscopy. . . . .	100
7.4.2	Mediastinoscopy . . . . .	101
7.4.3	Thoracoscopy. . . . .	102
7.4.4	Endoscopic Staging . . . . .	102
7.5	Palliative Surgery. . . . .	103
7.5.1	Pleural Drainage . . . . .	103
7.5.2	Pleurectomy . . . . .	103
7.6	Cytoreductive Surgery. . . . .	105
7.6.1	Extrapleural Pneumonectomy (EPP) . . . . .	105
7.6.2	Pleurectomy/Decortication (P/D) . . . . .	113
7.6.3	Intrapleural Therapies . . . . .	115
7.6.4	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication . . . . .	119
7.6.5	Does Cytoreductive Surgery Improve Survival? . . . . .	120
7.7	Summary . . . . .	121
	References . . . . .	121

<b>8</b>	<b>Chemotherapy and Radiotherapy for Mesothelioma</b> .....	127
	Xavier Dhalluin and Arnaud Scherpereel	
8.1	Introduction .....	127
8.2	Radiotherapy .....	128
8.2.1	Radical Radiotherapy .....	128
8.2.2	Prophylactic Radiotherapy .....	132
8.3	Systemic Therapies for Malignant Pleural Mesothelioma .....	133
8.3.1	Systemic Chemotherapy .....	133
8.3.2	Targeted Therapies .....	138
8.3.3	Immunomodulators, Gene Therapy and Cell Therapy .....	141
8.4	Conclusion .....	142
	References .....	142
<b>9</b>	<b>Genetics and Molecular Biology of Mesothelioma</b> .....	149
	Dean A. Fennell	
9.1	Apoptosis as a Tumor Suppressor Mechanism .....	149
9.2	Key Alterations in the Core Apoptosis Signaling in Mesothelioma ..	149
9.2.1	Regulation of the Intrinsic (Mitochondrial) Apoptosis Pathway in Mesothelioma .....	149
9.2.2	Extrinsic Apoptosis Pathway Regulation in Mesothelioma .....	152
9.2.3	Inhibitors of Apoptosis in Mesothelioma .....	152
9.3	Tumor Suppressor Loss in Mesothelioma .....	152
9.3.1	Loss of nf2 Is Frequent in Mesothelioma .....	152
9.3.2	NF2 Encodes the Tumor Suppressor Merlin .....	153
9.3.3	PLZF Is a Novel Tumor Suppressor in Mesothelioma .....	154
9.4	Therapeutic Inhibition of Survival Pathways .....	154
9.4.1	PI3K/AKT/mTOR Axis in Mesothelioma .....	154
9.4.2	HGF/cMET Pathway Is Activated in Mesothelioma .....	154
9.4.3	WNT Pathway Activation in Mesothelioma .....	155
9.4.4	Estrogen Receptor Beta .....	156
9.5	Therapeutic Reactivation of Tumor Suppressors .....	156
9.5.1	Epigenomic Dysregulation in Mesothelioma .....	156
9.5.2	Targeting the Mesothelioma Epigenome via Inhibition of Histone Deacetylases .....	157
9.5.3	Targeting the Ubiquitin Proteasome Pathway .....	158
9.6	Synthetic Lethal Strategies .....	158
9.7	Summary .....	159
	References .....	159

<b>10</b>	<b>Early Stages of Mesothelioma, Screening and Biomarkers</b> . . . . .	<b>169</b>
	Sonja Klebe and Douglas W. Henderson	
10.1	Early-Stage Malignant Mesothelioma, Including the Concept of Mesothelioma In Situ and the Distinction from Reactive Mesothelial Hyperplasia . . . . .	169
10.2	Biomarkers for Early-Stage Epithelioid Malignant Mesothelioma Versus Reactive Mesothelial Hyperplasia. . . . .	174
10.2.1	Epithelial Membrane Antigen (EMA) . . . . .	174
10.2.2	GLUT-1. . . . .	175
10.2.3	Bcl-2 . . . . .	176
10.2.4	p53 . . . . .	176
10.2.5	X-Linked Inhibitor of Apoptosis Proteins (XIAP). . . . .	177
10.2.6	P-Glycoprotein (P-170). . . . .	177
10.2.7	Neural Cell Adhesion Molecules (NCAMs): CD56. . . . .	177
10.3	Screening for Malignant Mesothelioma and Prognostic Biomarkers: Serum Levels of Soluble Mesothelin-Related Proteins (SMRPs), Osteopontin (OPN), Megakaryocyte Potentiating Factor (MKPF) and CA125 . . . . .	178
10.3.1	Introductory Remarks on Screening for Malignant Mesothelioma. . . . .	178
10.3.2	Radiological Screening for MM . . . . .	179
10.3.3	Soluble Mesothelin-Related Proteins (SMRPs) . . . . .	179
10.3.4	Serum Osteopontin (OPN) Levels . . . . .	181
10.3.5	Megakaryocyte Potentiating Factor (MKPF) . . . . .	182
10.3.6	CA125. . . . .	182
10.3.7	Summary. . . . .	182
10.4	Aquaporins and Malignant Mesothelioma . . . . .	183
	References. . . . .	185



Thomas A. Sporn

**Abstract** The term asbestos collectively refers to a group of naturally occurring fibrous minerals which have been exploited in numerous commercial and industrial settings and applications dating to antiquity. Its myriad uses as a “miracle mineral” owe to its remarkable properties of extreme resistance to thermal and chemical breakdown, tensile strength, and fibrous habit which allows it to be spun and woven into textiles. Abundant in nature, it has been mined considerably, and in all continents save Antarctica. The nomenclature concerning asbestos and its related species is complex, owing to the interest held therein by scientific disciplines such as geology, mineralogy and medicine, as well as legal and regulatory authorities. As fibrous silicates, asbestos minerals are broadly classified into the *serpentine* (chrysotile) and *amphibole* (crocidolite, amosite, tremolite, anthophyllite, actinolite) groups, both of which may also contain allied but nonfibrous forms of similar or even identical chemical composition, nonpathogenic to humans. Recently, fibrous amphiboles, not historically

classified or regulated as asbestos (winchite, richterite), have been implicated in the causation of serious disease due to their profusion as natural contaminants of vermiculite, a commercially useful and nonfibrous silicate mineral. Although generally grouped, classified, and regulated collectively as asbestos, the serpentine and amphibole groups have different geologic occurrences and, more importantly, significant differences in crystalline structures and chemical compositions. These in turn impart differences in fiber structure and dimension, as well as biopersistence, leading to marked differences in relative potency for causing disease in humans for the group of minerals known as asbestos.

---

## 1.1 Introduction and Historical Background

Minerals are naturally occurring, inorganic compounds of specific chemical composition and crystal structure. Their nomenclature typically stems as an honorific, to indicate a pertinent geographic area or to highlight a distinctive characteristic of the compound. Derived from the Greek asbestos (“unquenchable” or “indestructible”), asbestos is the collective term for a family of naturally occurring fibrous silicates that exist in metamorphic, altered basic, or ultra

---

T.A. Sporn  
Department of Pathology,  
Duke University Medical Center,  
200 Trent Drive, Durham, NC 27710, USA  
e-mail: sporn001@mc.duke.edu

1 basic igneous rock. Asbestos and asbestiform minerals are narrowly defined and classified, as will be discussed below. The asbestos minerals have found much utility owing to their common properties of thermochemical and electrical resistance, high tensile strength, and flexibility. Insoluble in water and organic solvents, its fine fibers may be spun and woven into textiles and incorporated into many other types of materials, asbestos has seen literally thousands of industrial applications. The usage of asbestos dates, through fact and fable, to thousands of years ago. Once believed to have almost magical capabilities, first descriptions document its usage in the manufacture of pottery in Finland ca. 2500 BC. Additional historical attributions for early asbestos usage include cremation garments for royalty and for embalming the pharaohs of ancient Egypt, and the emperor Charlemagne reportedly astonished his guests at a feast by throwing table cloths made from asbestos into a fire from which the garments would be removed clean and unharmed. Medieval alchemists termed the mineral “salamander stone” referring to a mythical fireproof animal, and during these times asbestos was used in suits of armor [1]. Deposits of asbestos in the Ural Mountains led to the development of factories producing asbestos textiles in 1720. In the seventeenth century, fibrous minerals discovered in Germany termed *Bergflachs* or *Bergleder* likely contained amphibole asbestos, and by the mid-nineteenth century, some 20 asbestos mines were operating in Europe [19]. In colonial America, asbestos deposits were discovered in Pennsylvania and New England, where it was woven into textiles, and chrysotile was discovered in Quebec, Canada in 1860 [19]. Significant commercial usage of asbestos did not occur until the latter part of the nineteenth century, with the development of the demand for insulation for the burgeoning steam technology. At the turn of the twentieth century, additional applications for the useful minerals had been developed, deposits of amphibole asbestos species had been discovered in South Africa,

and asbestos was once more being mined in the Urals, this time in large quantities. Commercial exploitation of asbestos was now global and full-blown, and by 1980 over 100 million tons of asbestos had been mined worldwide [19], accompanied by the development of serious health concerns related to its usage. It is the purpose of this chapter to describe what asbestos is from a mineralogic perspective, where it is to be found, and what are the important distinctions that allow relative differences within members of the asbestos group to have differing potencies on the basis of such differences in terms of inducing injury and producing disease following inhalation. It is well known from animal models that the oncogenic potential of fibrous dust increases following reductions in fiber diameter, and decreases with reduction in fiber length, and these considerations are generally more important than the chemical composition of the fibers themselves [5, 6, 16, 21]. The longer fibers have more potency to induce cell injury, proliferation, oxidant release, and inflammation. It is also the durability of the fibrous dust that confers biopersistence, and the potential to induce malignant disease following deposition of fibers in the peripheral airways and migration of fibers to the serosal membrane. Contemporary usage of asbestos has been curtailed following its wide recognition as a most dangerous substance; it is noteworthy that the health hazards of asbestos date to antiquity as well. Pliny the Elder cautioned against the purchase of quarry slaves from asbestos mines, noting that they tended to die young [1].

---

## 1.2 Geologic and Mineralogic Features

Asbestos is properly considered a commercial and legal rather than a mineralogic term for a group of fibrous silicate minerals with crystalline structure and by definition have lengths  $>5 \mu\text{m}$  and aspect (length: diameter) ratios of

3 or greater. In the USA, the nomenclature as defined by the Environmental Protection Agency encompasses six unique mineral species, conventionally divided into two distinct groups, the amphiboles and the serpentines [22]. Chrysotile is the sole member of the latter group, and as of the year 2000, accounted for virtually 100% of the asbestos used commercially. Historically, at least 90% of commercially used asbestos has been chrysotile. The amphibole group contains grunerite-cummingtonite (amosite, *vide infra*), crocidolite (a fibrous variant of riebeckite), tremolite, actinolite, and anthophyllite. The name amosite is derived from the acronym AMOSA – Asbestos Mines of South Africa –giving reference to the company in the Transvaal Province of South Africa, the sole mine producing the mineral. As such, amosite, too, is a commercial, rather than a true mineralogic term, but by convention, amosite is used synonymously for the fibrous forms of grunerite-cummingtonite, just as crocidolite for the fibrous form of riebeckite. Among the amphiboles, only crocidolite and amosite have undergone significant commercial exploitation in industrialized countries, and collectively account for less than 10% of asbestos utilized in the last century. Large amounts of amosite were imported into the USA during World War II for

usage in warship and merchant vessel insulation. The so-called noncommercial amphiboles, actinolite, tremolite, and anthophyllite, are common mineral species with wide distribution. They are relevant insofar as they are contaminants of other commercially useful mineral species such as talc and vermiculite, as well as chrysotile, and have been implicated in the induction of disease in humans. The asbestos minerals have nonpathogenic, nonasbestiform mineral counterparts of identical chemical composition. The noncommercial species of amphiboles all require the word “asbestos” after their mineral name for the purpose of distinguishing them from the nonasbestos forms. This is not necessary for crocidolite, amosite, and chrysotile as the nonasbestos forms have different names as discussed above (see Fig. 1.1).

Asbestos minerals owe their fibrous habit to the parallel growth of very fine and elongate crystals, producing bundles. The amphiboles may also occur as nonfibrous, chunky, acicular and shard-like forms. Nonfibrous serpentine minerals include antigorite and lizardite. The nonfibrous forms of both serpentine and amphibole minerals are more common and widespread than the asbestiform species.

Deposits of commercial asbestos are to be found in four types of rocks: the banded




Fig. 1.1 Classification of asbestos and asbestiform silicates

ironstones, containing amosite and crocidolite; the alpine-type ultramafic rocks, containing chrysotile, anthophyllite, and tremolite; stratiform ultramafic inclusions, containing chrysotile and tremolite; and serpentinized limestone (chrysotile) [19].

### 1.3 Distribution and Physicochemical Properties of Chrysotile

Chrysotile is a common serpentine mineral with worldwide distribution, and the only one of this series mined as asbestos. The type 1 (alpine type, ultramafic rock) deposits are the most important sources of chrysotile asbestos, with principal localities occurring in the Ural Mountains of Russia and the Appalachian Mountains of the Canadian province of Quebec and the state of Vermont in the USA, as well as the state of California. Chrysotile has also been mined in the Italian Alps, Cypress, Zimbabwe, and the People's Republic of China [19] (Table 1.1). Commercially useful chrysotile is prepared from chrysotile ore in the milling process, with extracted long fiber

chrysotile finding usage in textiles, and shorter fibers used in construction materials such as joint compound. Among the commercially exploited seams of the mineral, geographic variations are to be expected, both in terms of physical characteristics of the fibers, type, as well as proximity to fibrous species of noncommercial amphiboles. For example, the rich chrysotile ores quarried at the Coalinga, California yield fibers almost exclusively less than  $5\ \mu\text{m}$  [9]. There is also variance in the presence of other potentially dangerous minerals even within neighboring seams. McDonald et al attributed the difference in reported deaths due to mesothelioma among workers in several different mines within the province of Quebec to be attributable to local variances in the amount of tremolite contamination known to exist within the various mines [12]. The topic of chrysotile purity following milling, and the potential contamination by non-commercial species, is frequently argued in the ongoing asbestos litigation in the USA.

Silicates may be classified on the basis of the polymerization type of the silicate ions and the variance in crystalline structure that occurs through association of various cations. Chrysotile is a hydrated (approximately 13% water as a crystal), phyllosilicate (sheet silicate) with chemical composition  $\text{Mg}_3\text{Si}_2\text{O}_5(\text{OH})_4$ , containing the  $(\text{Si}_2\text{O}_5)_n^{-2}$  building block typical of the serpentine group of minerals [4] (Fig. 1.2). Whereas other serpentines and other layered silicates (clays, mica) form flat sheets, spatial imbalances between magnesium and silica ions within the tetrahedral and octahedral sheets of chrysotile cause the layers to roll to form concentric hollow cylinders. Chrysotile fibers will thus appear scroll-like when viewed end on (Fig. 1.3), containing a central capillary with 2–4.5 nm in diameter. The milling of chrysotile ore yields bundles of fibers of variable length, and some fibers may exceed  $100\ \mu\text{m}$ . The fibers may be curvilinear (“serpentine”), often with splayed ends due to the separation of fibers into individual and smaller fibrillar units (Fig. 1.4).

**Table 1.1** Geographic distribution of asbestos species

Asbestos mineral	Geographic distribution
Chrysotile	Canada (Quebec), USA (Vermont, California), Russia, China
Crocidolite	South Africa (NW Cape Province, Transvaal), Western Australia
Amosite	South Africa
Tremolite	Turkey, Cyprus, Greece
Anthophyllite	Finland, USA
Actinolite	South Africa (Cape Province)
Winchite/Richterite <sup>a</sup>	USA (Montana)

<sup>a</sup>Asbestiform amphibole species, not classified as asbestos





Fig. 1.2 Chemical composition and elemental spectra of asbestos

Some very long chrysotile fibers may be quite thin, but the diameter of chrysotile fibers tends to increase with increasing fiber length. Magnesium is an important constituent of both chrysotile and the amphiboles; the presence of soluble magnesium molecules on the outside of the curled chrysotile structure permits its leaching at the surface, facilitating the breakdown of fibers, within lung tissue, into successively


smaller, fragile fibrils, which are then readily cleared from the body. Loss of magnesium changes the surface charge from positive to negative, which diminishes the oncogenic potential [16]. The clearance halftime of inhaled chrysotile within the lower respiratory tract is measured in only weeks, and may be much less. For example, with a clearance halftime measured in hours, the Calidria chrysotile from California is among

1

**Fig. 1.3** Crystalline structure of chrysotile (Schematic diagram modified from [18])



**Fig. 1.4** Chrysotile asbestos fibers, scanning electron photomicrograph. Note long fibers of variable thickness and curvilinear “serpentine” morphology



the mineral fibers with the most rapid clearance from the lung. Other chrysotile may have biopersistence similar to the range reported for glass and stone wools [3]. Thermoresistant to a degree, 70% of the chrysotile structure is lost at 575°C, with complete loss of the structure occurring at 650°C [10]. Such high temperatures may be observed in the automotive braking process,

causing pyrolysis and conversion to the nonfibrous, nonpathogenic silicate mineral forsterite [10]. Due to its physicochemical characteristics, chrysotile has a greatly reduced biopersistence in contrast to the amphibole species, and those features as described above provide a likely explanation for the reported reductions in oncogenicity for this species in humans in contrast to

the amphiboles [2, 17], and for the epidemiologic studies that conclude that motor vehicle mechanics performing brake repair are not at increased risk for developing mesothelioma [8].

---

## 1.4

### **Distribution and Physicochemical Properties of the Amphibole Species**

The amphibole asbestos minerals crocidolite, amosite, anthophyllite, tremolite, and actinolite are inosilicates, or chain silicates. Tremolite, actinolite, and anthophyllite are grouped together with chrysotile as “white asbestos” and classified under the United Nations chemical identification schema as UN2590. Amosite “brown asbestos” and crocidolite “blue asbestos” are classified as UN2212. Amphiboles typically occur when veins of the mineral are created when cracks form in rocks during movement of the earth. These conditions help provide the environment necessary for massive amphibole crystallization and transformation to the fibrous form. The amphibole minerals are common, but their occurrence as exploitable forms is limited to certain locations where they obtain the proper physicochemical characteristics and abundance to be used as commercial asbestos. The major deposits of commercial amphiboles have generally been limited to the banded ironstones of Western Australia and the Transvaal and Cape Provinces of South Africa. Alpine-type and stratiform ultramafic rock are sources of chrysotile, as well as the noncommercial amphiboles tremolite, actinolite, and anthophyllite, the major source for the latter occurring in Finland with smaller deposits in rocky outcrops of the USA [19]. Another source of asbestiform amphiboles is to be found in the area around Libby, Montana, USA. Libby is the site of the largest mined deposit of vermiculite in the world, and the alkaline-ultramafic rock is rich in amphiboles, chiefly richterite and

winchite (sodic-calcic tremolite), all of which can exist in asbestiform or fibrous habit [15, 23]. The latter species are not listed in the US Federal Regulations governing asbestos, but their recognition is important in view of the abnormally high number of asbestos-related diseases and deaths in former vermiculite miners and millers and residents of this area, and the potency of the Libby amphibole in terms of inducing mesothelioma is reported to be similar to crocidolite [7, 13, 14]. Anthophyllite, tremolite, and actinolite are common constituents of the earth’s crust, but have not been exploited commercially in industrialized countries, and are frequently associated with serpentine minerals, vermiculite, and talc. The noncommercial amphiboles may assume a variety of forms, including nonfibrous forms.

The chemical and crystalline structures of the amphiboles are highly similar, and generally may be distinguished only on the basis of chemical composition, and in specific the cation constituents (Fig. 1.2). Crystalline amphibole minerals demonstrate perfect prismatic cleavage, with direction of the cleavage parallel to the length of the silicate chains [20]. The silicate chains are formed by linear arrays of  $\text{SiO}_4$  tetrahedra linked by octagonal groups of cations, and may be of significant length (Fig. 1.5). The crystalline amphibole fibers are substantially more brittle than chrysotile, limiting their potential for fabrication. These mineralogic attributes confer the potential for great fiber length, and accordingly, significant pathogenicity following deposition in the lung (Figs. 1.6–1.9). As their straight, broad fibers are resistant to fiber fragmentation and chemical degradation in the body, the biopersistence of the amphiboles is much greater than chrysotile, and their clearance half-time is generally measured in decades. The crystalline structure of the amphiboles also contains less water than chrysotile, and there is greater resistance to pyrolysis. Amphibole fibers are less flexible than chrysotile, permitting greater friability with potential to release respirable particles.